Privium Fund Management’s Japer Therapeutics Warrants JSPRW Stock Holding History

Privium Fund Management’s Portfolio JSPRW Stock Details JSPRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-98,202	Closed	-$3.33K	–	137
2022 Q4	$3.33K	Buy	98,202 +100	+0.1%	+$4	﹤0.01%	122
2022 Q3	$6K	Buy	98,102 +91	+0.1%	+$8	﹤0.01%	159
2022 Q2	$9K	Hold	98,011	–	–	﹤0.01%	168
2022 Q1	$25K	Hold	98,011	–	–	0.01%	186
2021 Q4	$153K	Buy	+98,011	New	+$137K	0.03%	118

Other funds holding JSPRW

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

ICM

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

Zazove Associates Incline Village, Nevada $1.22B AUM 1.91% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Privium Fund Management's JSPRW Position: Q1 2023 in Review

Privium Fund Management sold out of Japer Therapeutics Warrants (JSPRW) in Q1 2023, closing a stake of 98,202 shares — an estimated $3.33K sold.

Privium Fund Management first reported a position in JSPRW in Q4 2021 and held it in 5 quarters. The position peaked at $153K in Q4 2021. 10 funds tracked by Wall St. Rank hold JSPRW as of Q1 2023.

Privium Fund Management reported no remaining Japer Therapeutics Warrants position as of Q1 2023 after selling out during the quarter.
Privium Fund Management sold 98,202 Japer Therapeutics Warrants shares in Q1 2023, an estimated $3.33K.
Privium Fund Management first reported a position in Japer Therapeutics Warrants in Q4 2021 and held it in 5 quarters.
Privium Fund Management's Japer Therapeutics Warrants position peaked at $153K in Q4 2021.
10 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q1 2023.

Based on Privium Fund Management's 13F filing for Q1 2023, filed 3 May 2023.